US4462998A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of using a cis-platinum(II) amine ascorbate
Assignee: BASF Catalysts LLC
•
Filing: 1983-11-04
•
Granted: 1984-07-31
•
Expires: 2003-11-04
Abstract
Abstract A pharmaceutical composition in which the active ingredient is an ascorbate complex of platinum (II) coordinated to ammonia, a monodentate amine ligand or a bidentate amine ligand as, for example, an alkylamine, an alkylenediamine or a cycloalkylamine. Said compositions are useful in the treatment of malignant tumors in animals. They may be administered orally or parenterally and they exhibit high solubility in water and low toxicity.
Inventors
- 👤 Alan R. Amundsen
- 👤 Eric W. Stern
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-06 00:36
CPC Classifications
C; C07; C07F; C07F15/00; C07F15/0006; C07F15/0086; C07F15/0093
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
122 words
A method for treating animal malignant tumor cells sensitive to a platinum complex of the formula: cis-[Pt(II)A.sub.2 (X).sub.m (OH).sub.n ] wherein Pt is in valence state II and is coordinated to A in a cis configuration, A is ammonia or a monodentate alkylamine ligand, A 2 is a bidentate amine ligand, X is the ascorbate moiety, m is an integer having a value of from 1 to 2, n is an integer having a value of from 0 to 1 and the sum of m and n is not greater than 2; which comprises administering to an animal afflicted with said tumor cells an effective amount of cis-[Pt(II)A 2 (X) m (OH) n ] sufficient to cause regression of said tumor cells.
Claim 2
Independent Claim
122 words
A method for treating animal malignant tumor cells sensitive to a platinum complex of the formula: cis-[Pt(II)A.sub.2 (X).sub.m (OH).sub.n ] wherein Pt is in valence state II and is coordinated to A in a cis configuration, A is ammonia or a monodentate alkylamine ligand, A 2 is a bidentate amine ligand, X is the ascorbate moiety, m is an integer having a value of from 1 to 2, n is an integer having a value of from 0 to 1 and the sum of m and n is not greater than 2; which comprises administering to an animal afflicted with said tumor cells an effective amount of cis-[Pt(II)A 2 (X) m (OH) n ] sufficient to cause regression of said tumor cells.
Claim 3
Dependent Claim
22 words
The method of claim 1 wherein said complex is selected from the group consisting of cis-diammineplatinum(II) ascorbate and cis-bis(lower alkylamine) platinum(II) ascorbate.
Claim 4
Dependent Claim
11 words
The method of claim 2 wherein said complex is cis-diammineplatinum(II) ascorbate.
Claim 5
Dependent Claim
12 words
The method of claim 2 wherein said complex is cis-bis(lower alkylamine)platinum(II) ascorbate.
Claim 6
Dependent Claim
11 words
The method of claim 4 wherein said complex is cis-bis(methylamine)platinum(II) ascorbate.
Claim 7
Dependent Claim
85 words
The method of claim 1 wherein A 2 in the complex cis-[Pt(II)A 2 (X) m (OH) n ] represents a bidentate amine ligand of the formula: ##STR3## wherein each of R 1 and R 2 , taken separately, is selected from the group consisting of hydrogen and lower alkyl, or R 1 and R 2 , taken together, afford a 1,2-diaminocycloalkane ligand containing from about 4-8 nuclear carbon atoms which may be optionally substituted by one or more linear or branched chain lower alkyl groups.
Claim 8
Dependent Claim
11 words
The method of claim 6 wherein said complex is ethylenediamineplatinum(II) ascorbate.
Claim 9
Dependent Claim
11 words
The method of claim 6 wherein said complex is 1,2-diaminocyclohexaneplatinum(II) ascorbate.
Claim 10
Dependent Claim
22 words
The method of claim 1 wherein the complex: cis-[Pt(II)A 2 (X) m (OH) n ] represents a mixture of cis-diammineplatinum(II) ascorbate complexes.
Claim 11
Dependent Claim
11 words
The method of claim 1 wherein said complex is administered parenterally.
Claim 12
Dependent Claim
11 words
The method of claim 1 wherein said complex is administered orally.
Claim 13
Dependent Claim
14 words
The method of claim 1 wherein said complex is administered in a single dose.
Claim 14
Dependent Claim
13 words
The method of claim 1 wherein said complex is administered in multiple doses.
References Cited (Backward Citations)
GB488784A
Cited
FR3385M
Cited
US4140707A
Cited
US4140707B1
Cited
US4211712A
Cited
US4234500A
Cited
US4234499A
Cited
US4248840A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1987-07-31 | 1988-01-30 | 1988-07-31 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1991-07-31 | 1992-01-30 | 1992-07-31 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1995-07-31 | 1996-01-30 | 1996-07-31 | $7700.00 | Window Closed / Lapsed |